

Relationship between disease severity and quality of life, health care utilization and cost for ulcerative colitis in Australia: A cross-sectional study

Journal of Crohn's and Colitis

8, 598-606

DOI: [10.1016/j.crohns.2013.11.017](https://doi.org/10.1016/j.crohns.2013.11.017)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impact of Inflammatory Bowel Disease on Disability. <i>Current Gastroenterology Reports</i> , 2014, 16, 414.	1.1	29
2	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. <i>European Journal of Health Economics</i> , 2014, 15, 121-128.	1.4	41
3	Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2576-2582.	0.9	13
4	Long-term outcomes of colectomy surgery among patients with ulcerative colitis. <i>SpringerPlus</i> , 2015, 4, 573.	1.2	34
5	Web-based interventions for ulcerative colitis and Crohn's disease: systematic review and future directions. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 149.	1.0	10
6	The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 625-632.	0.6	31
7	The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX [®] formulated delayed-release mesalamine. <i>Quality of Life Research</i> , 2015, 24, 671-683.	1.5	8
8	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1760-1766.	2.4	62
9	Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 840-846.	0.9	6
10	Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1066-1078.	1.9	31
11	Is It Possible to Identify Patients With Inflammatory Bowel Disease Who Are at Risk for Cytomegalovirus Infection?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 138-139.	2.4	0
12	Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland. <i>PLoS ONE</i> , 2016, 11, e0168586.	1.1	22
13	Illness perceptions and stress: mediators between disease severity and psychological well-being and quality of life among patients with Crohn's disease. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2387-2396.	0.8	53
14	Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease. <i>Patient Preference and Adherence</i> , 2016, Volume 11, 23-31.	0.8	23
15	The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: Focus on genetic and genomic technologies. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 119-133.	1.5	17
16	Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1056-1064.	0.8	21
17	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, 592-600.	0.4	37
18	Health care costs associated with Australian tertiary inflammatory bowel disease care. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 851-856.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1818-1824.	1.4	16
20	Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 613-621.	1.4	12
21	The Long-Term Trends of the Association Between Falls Among the Elderly in Taiwan and their Utilization of Medical Facilities. <i>International Journal of Gerontology</i> , 2017, 11, 161-165.	0.7	3
22	The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 749-759.	1.4	27
23	Cost of Ulcerative Colitis in Quebec, Canada. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1262-1271.	0.9	15
24	Health Care Services in IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1461-1469.	0.9	15
25	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 264-275.	1.9	39
26	Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 165-174.	0.6	110
27	A Comparison of the Validity and Responsiveness of the EQ-5D-5L and SF-6D for Measuring Health Spillovers: A Study of the Family Impact of Meningitis. <i>Medical Decision Making</i> , 2017, 37, 882-893.	1.2	25
28	Improved Medical Treatment and Surgical Surveillance of Children and Adolescents with Ulcerative Colitis in the United Kingdom. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1520-1530.	0.9	3
29	Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 450-463.	0.9	10
30	Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. <i>United European Gastroenterology Journal</i> , 2018, 6, 138-147.	1.6	9
31	Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 22.	0.9	5
32	Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. <i>Quality of Life Research</i> , 2018, 27, 273-290.	1.5	29
33	Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 62.	0.9	22
34	Validation of a self-reported work disability questionnaire for ulcerative colitis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.4	1
35	Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1918-1925.	0.9	22
36	Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. <i>Przegląd Gastroenterologiczny</i> , 2018, 13, 61-68.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	1.3	27
38	Cost per response/remission in biologics available in Italy for the treatment of TNF- $\hat{\pm}$ inhibitors-na $\hat{\sim}$ ve patients with ulcerative colitis. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031882243.	0.2	0
39	Exploring the therapeutic potential of sodium benzoate in acetic acid-induced ulcerative colitis in rats. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2019, 30, .	0.7	6
40	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1399-1407.	0.9	27
41	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, S17-S33.	0.1	63
42	Impact of inflammatory bowel diseases on working life: A French nationwide survey. <i>Digestive and Liver Disease</i> , 2019, 51, 961-966.	0.4	27
43	Quality of Life in Patients With Healthy and Diseased Ileal Pouch. , 2019, , 335-341.		1
44	Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. <i>Endoscopy International Open</i> , 2019, 07, E568-E575.	0.9	22
45	Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1138-1147.	0.6	15
46	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). <i>BMJ Open</i> , 2019, 9, e030134.	0.8	4
47	The Impact of Revascularisation on Quality of Life in Chronic Mesenteric Ischemia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-7.	0.8	10
48	Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. <i>Scientific Reports</i> , 2019, 9, 17751.	1.6	6
49	Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. <i>Gut</i> , 2019, 68, 623-632.	6.1	22
50	Polysaccharides derived from <i>Morinda citrifolia</i> Linn reduce inflammatory markers during experimental colitis. <i>Journal of Ethnopharmacology</i> , 2020, 248, 112303.	2.0	38
51	Malnutrition and quality of life among adult inflammatory bowel disease patients. <i>JGH Open</i> , 2020, 4, 454-460.	0.7	23
52	Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 205-215.	0.8	4
53	Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000456.	1.1	3
54	The amelioration of ulcerative colitis induced by Dinitrobenzenesulfonic acid with <i>Radix Hedysari</i> . <i>Journal of Food Biochemistry</i> , 2020, 44, e13421.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 758-765.	0.5	12
56	Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102358.	0.9	12
57	Cost-Effectiveness Analysis of Four Common Diagnostic Methods for <i>Clostridioides difficile</i> Infection. <i>Journal of General Internal Medicine</i> , 2020, 35, 1102-1110.	1.3	6
58	Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 5-21.	0.7	38
59	The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. <i>Quality of Life Research</i> , 2021, 30, 1925-1938.	1.5	3
60	Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 91-102.	1.0	10
61	Treat-to-target approach in the management of inflammatory Bowel disease. <i>Gastroenterology & Hepatology</i> , 2021, 44, 312-319.	0.2	11
62	Treat-to-target approach in the management of inflammatory Bowel disease. <i>Gastroenterology & Hepatology</i> (English Edition), 2021, 44, 312-319.	0.0	0
63	Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventonal, observational study in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e615-e624.	0.8	4
64	Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. <i>Frontiers in Public Health</i> , 2021, 9, 675523.	1.3	59
65	Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	13
66	The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>Journal of Patient-centered Research and Reviews</i> , 2020, 7, 189-205.	0.6	22
67	A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15994.	0.5	8
68	Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. , 2019, 8, 1307.		5
69	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. <i>Health Technology Assessment</i> , 2016, 20, 1-326.	1.3	41
70	Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. <i>World Journal of Gastroenterology</i> , 2019, 25, 5862-5882.	1.4	44
71	Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea. <i>Gut and Liver</i> , 2020, 14, 459-467.	1.4	15
73	Burden of Inflammatory Bowel Disease on Patient Mood, Fatigue, Work and Health-Related Quality of Life in Thailand: A Case-Control Study. <i>Crohn's & Colitis</i> 360, 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
74	Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. <i>American Health and Drug Benefits</i> , 2014, 7, 289-97.	0.5	18
75	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). <i>Innovations in Pharmacy</i> , 2020, 11, .	0.2	0
76	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). <i>Innovations in Pharmacy</i> , 2020, 11, 17.	0.2	0
77	Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis. <i>Gut and Liver</i> , 2022, 16, 736-745.	1.4	3
78	The impact of symptom severity on the humanistic and economic burden of inflammatory bowel disease: a real-world data linkage study. <i>Current Medical Research and Opinion</i> , 2022, 38, 541-551.	0.9	5
79	Health-related quality of life among Chinese patients with Crohn's disease: a cross-sectional survey using the EQ-5D-5L. <i>Health and Quality of Life Outcomes</i> , 2022, 20, 62.	1.0	2
80	Work-related productivity loss and associated indirect costs in patients with Crohn's disease or ulcerative colitis in the United States. <i>Crohn's & Colitis</i> 360, 0, , .	0.5	2
81	Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: the Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ). <i>Frontline Gastroenterology</i> , 2023, 14, 59-67.	0.9	0
82	Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study. <i>Current Drug Safety</i> , 2022, 17, .	0.3	1
83	Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 513-523.	0.6	1
85	Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records. <i>Upsala Journal of Medical Sciences</i> , 0, 127, .	0.4	3
86	Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 99-108.	1.4	2
87	Has the COVID-19 Pandemic Worsened Health-Related Quality of Life of Patients with Inflammatory Bowel Disease? A Longitudinal Disease Activity-Controlled Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1103.	1.2	1
88	A biobehavioural and social-structural model of inflammation and executive function in pediatric chronic health conditions. <i>Health Psychology Review</i> , 2024, 18, 24-40.	4.4	0
89	Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1421-1430.	0.9	3
90	Multi-item Measures for Paediatric Inflammatory Bowel Diseases: The ABCs of All Those Acronyms. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1154-1168.	0.6	3
91	The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 458-492.	3.7	26
92	A Systematic Review of Self-Management Interventions for Patients with Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2023, 8, 1-12.	0.8	2

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------